1 Introduction Uncontrolled hypertension is the leading preventable cause of death globally [1], and is associated with a particularly high risk of adverse cardio-kidney-metabolic (CKM) outcomes, including metabolic dysfunction–associated steatotic liver disease (MASLD), type 2 diabetes (T2D), chronic kidney disease (CKD) and major adverse cardiovascular events (MACE) [2].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Matthew Anson
Progression to type 1 diabetes across the autoimmunity and glycaemia continuum: Insights from real-world paediatric and adult cohorts
Real-world scale: This is one of the largest real-world analyses of progression from islet autoimmunity to type 1 diabetes. It includes 7000 autoantibody-positive children and adults from routine electronic health records. Routine HbA1c predicts risk: Mildly raised HbA1c which is measured in routine care is associated with faster progression in people with a single autoantibody compared to more preserved HbA1c (adults [HR 2.94]; children [HR 1.44]).
Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement
1 BACKGROUND Type 1 diabetes (T1D) is a chronic autoimmune disease, typically diagnosed in childhood and adolescence, characterised by immune-mediated destruction of pancreatic β-cells.
Target Trial Emulations of GLP‐1 and Dual GLP‐1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes
In this study of real-world data, we find that two drugs, semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), reduced the risk of major liver problems in people with type 2 diabetes by 28% and 39%, respectively, compared to another common diabetes treatment. Liraglutide, another similar drug, did not show this same benefit.
The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database
Keywords Type 2 diabetes Epidemiology Microvascular Macrovascular 1 Introduction Diabetes is a chronic metabolic disease associated with significant morbidity, mortality, and global health expenditure; attributable for 966 billion USD per year [1]. In 2021, it was estimated that 529 million people worldwide lived with diabetes, a 6.1 % global prevalence [2], expected to increase to 12.2 % by 2045.
Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD
BMI body mass index CVD cardiovascular disease HbA1c haemoglobin A1c HSI Hepatic Steatosis Index ICD-10 International Classification of Diseases, 10th Revision MASLD metabolic dysfunction-associated steatotic liver disease MetALD metabolic dysfunction-associated liver disease MetS metabolic syndrome NAFLD nonalcoholic fatty liver disease RF risk factor T2D type 2 diabetes Our study found that people with excess fat in their liver have a higher risk of heart disease, kidney disease, eye...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Matthew
Contact Matthew, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack